Published in J Neurodev Disord on April 02, 2013
Fragile X spectrum disorders. Intractable Rare Dis Res (2014) 0.91
Modeling fragile X syndrome in the Fmr1 knockout mouse. Intractable Rare Dis Res (2014) 0.88
High-Throughput Screening to Identify Compounds That Increase Fragile X Mental Retardation Protein Expression in Neural Stem Cells Differentiated From Fragile X Syndrome Patient-Derived Induced Pluripotent Stem Cells. Stem Cells Transl Med (2015) 0.87
Cardiac autonomic regulation in autism and Fragile X syndrome: a review. Psychol Bull (2014) 0.78
Parent-delivered touchscreen intervention for children with fragile X syndrome. Intractable Rare Dis Res (2014) 0.78
Association between macroorchidism and intelligence in FMR1 premutation carriers. Am J Med Genet A (2014) 0.76
Detection and Quantification of the Fragile X Mental Retardation Protein 1 (FMRP). Genes (Basel) (2016) 0.75
Reduced vagal tone in women with the FMR1 premutation is associated with FMR1 mRNA but not depression or anxiety. J Neurodev Disord (2017) 0.75
Recent advances in assays for the fragile X-related disorders. Hum Genet (2017) 0.75
A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen (1999) 32.67
The mGluR theory of fragile X mental retardation. Trends Neurosci (2004) 8.88
Absence of expression of the FMR-1 gene in fragile X syndrome. Cell (1991) 7.04
Correction of fragile X syndrome in mice. Neuron (2007) 6.51
The FMR-1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation. Nat Genet (1993) 4.57
The fragile X syndrome protein FMRP associates with BC1 RNA and regulates the translation of specific mRNAs at synapses. Cell (2003) 4.34
FMR1 and the fragile X syndrome: human genome epidemiology review. Genet Med (2001) 3.84
Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev (2008) 3.57
Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med (2011) 3.46
Advances in the treatment of fragile X syndrome. Pediatrics (2009) 3.10
Acetylated histones are associated with FMR1 in normal but not fragile X-syndrome cells. Nat Genet (1999) 2.59
A quantitative ELISA assay for the fragile x mental retardation 1 protein. J Mol Diagn (2009) 1.33
Mosaic FMR1 deletion causes fragile X syndrome and can lead to molecular misdiagnosis: a case report and review of the literature. Am J Med Genet A (2008) 1.21
SIRT1 inhibition alleviates gene silencing in Fragile X mental retardation syndrome. PLoS Genet (2008) 1.16
Noninvasive test for fragile X syndrome, using hair root analysis. Am J Hum Genet (1999) 0.95
A nonsense mutation in FMR1 causing fragile X syndrome. Eur J Hum Genet (2011) 0.92
Novel one-step immunoassays to quantify α-synuclein: applications for biomarker development and high-throughput screening. J Biol Chem (2012) 0.90
Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron (2012) 4.48
Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. J Biol Chem (2010) 2.10
HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration. PLoS Biol (2013) 1.96
Structural basis of ubiquitin recognition by the deubiquitinating protease USP2. Structure (2006) 1.92
Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients. J Clin Invest (2015) 1.74
Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease. J Clin Invest (2011) 1.66
Suppression of protein aggregation by chaperone modification of high molecular weight complexes. Brain (2012) 1.42
SIRT2 ablation has no effect on tubulin acetylation in brain, cholesterol biosynthesis or the progression of Huntington's disease phenotypes in vivo. PLoS One (2012) 1.27
The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease. Mol Neurodegener (2010) 1.18
K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo. PLoS One (2012) 1.16
Biochemical characterization of USP7 reveals post-translational modification sites and structural requirements for substrate processing and subcellular localization. FEBS J (2007) 1.14
HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation. Brain (2014) 1.13
TR-FRET-based duplex immunoassay reveals an inverse correlation of soluble and aggregated mutant huntingtin in huntington's disease. Chem Biol (2012) 1.13
Aspartic proteases in drug discovery. Curr Pharm Des (2007) 1.12
Mutant huntingtin impairs immune cell migration in Huntington disease. J Clin Invest (2012) 1.11
High LRRK2 levels fail to induce or exacerbate neuronal alpha-synucleinopathy in mouse brain. PLoS One (2012) 1.03
Modulation of inositol 1,4,5-triphosphate concentration by prolyl endopeptidase inhibition. Eur J Biochem (2002) 1.00
A screen for enhancers of clearance identifies huntingtin as a heat shock protein 90 (Hsp90) client protein. J Biol Chem (2011) 0.98
Activation of muscle-specific receptor tyrosine kinase and binding to dystroglycan are regulated by alternative mRNA splicing of agrin. J Biol Chem (2006) 0.95
Subcellular localization suggests novel functions for prolyl endopeptidase in protein secretion. J Neurochem (2005) 0.94
Development of a method for the high-throughput quantification of cellular proteins. Chembiochem (2009) 0.93
Novel one-step immunoassays to quantify α-synuclein: applications for biomarker development and high-throughput screening. J Biol Chem (2012) 0.90
Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3). Hum Mol Genet (2012) 0.89
Synthesis and characterization of fluorescent ubiquitin derivatives as highly sensitive substrates for the deubiquitinating enzymes UCH-L3 and USP-2. Anal Biochem (2005) 0.89
Inhibition of mammalian legumain by Michael acceptors and AzaAsn-halomethylketones. Biol Chem (2002) 0.87
Fibroblast growth factor receptors as novel therapeutic targets in SNF5-deleted malignant rhabdoid tumors. PLoS One (2013) 0.86
Optimization of an HTRF Assay for the Detection of Soluble Mutant Huntingtin in Human Buffy Coats: A Potential Biomarker in Blood for Huntington Disease. PLoS Curr (2010) 0.85
c-Src-mediated epithelial cell migration and invasion regulated by PDZ binding site. Mol Cell Biol (2007) 0.85
Huntingtin cleavage product A forms in neurons and is reduced by gamma-secretase inhibitors. Mol Neurodegener (2010) 0.85
Onset and progression of behavioral and molecular phenotypes in a novel congenic R6/2 line exhibiting intergenerational CAG repeat stability. PLoS One (2011) 0.83
A novel class of oral direct renin inhibitors: highly potent 3,5-disubstituted piperidines bearing a tricyclic p3-p1 pharmacophore. J Med Chem (2013) 0.83
Regulation of c-Src by binding to the PDZ domain of AF-6. EMBO J (2007) 0.83
Neuronal aggregates are associated with phenotypic onset in the R6/2 Huntington's disease transgenic mouse. Behav Brain Res (2012) 0.83
Crystal structure of an activation intermediate of cathepsin E. J Mol Biol (2004) 0.83
Characterisation of human dipeptidyl peptidase IV expressed in Pichia pastoris. A structural and mechanistic comparison between the recombinant human and the purified porcine enzyme. Biol Chem (2003) 0.82
Perturbation with intrabodies reveals that calpain cleavage is required for degradation of huntingtin exon 1. PLoS One (2011) 0.82
Caspase-6 does not contribute to the proteolysis of mutant huntingtin in the HdhQ150 knock-in mouse model of Huntington's disease. PLoS Curr (2012) 0.81
Fragments of HdhQ150 mutant huntingtin form a soluble oligomer pool that declines with aggregate deposition upon aging. PLoS One (2012) 0.81
Crystal structure of human BACE2 in complex with a hydroxyethylamine transition-state inhibitor. J Mol Biol (2005) 0.81
The PDZ protein MPP2 interacts with c-Src in epithelial cells. Exp Cell Res (2009) 0.80
A new method to determine the structure of the metal environment in metalloproteins: investigation of the prion protein octapeptide repeat Cu(2+) complex. Eur Biophys J (2004) 0.79
Transgenic expression of β1 antibody in brain neurons impairs age-dependent amyloid deposition in APP23 mice. Neurobiol Aging (2013) 0.79
Backbone 1H, 13C, and 15N resonance assignments for the 26-kD human de-ubiquitinating enzyme UCH-L3. Biomol NMR Assign (2007) 0.78
The configuration of the Cu2+ binding region in full-length human prion protein. Eur Biophys J (2007) 0.78
End-expiratory lung volumes and density distribution patterns during partial liquid ventilation in healthy and oleic acid-injured sheep: a computed tomography study. Crit Care Med (2003) 0.78
Transcriptional activation of the utrophin promoter B by a constitutively active Ets-transcription factor. Neuromuscul Disord (2003) 0.78
Clemastine causes immune suppression through inhibition of extracellular signal-regulated kinase-dependent proinflammatory cytokines. J Allergy Clin Immunol (2011) 0.77
Genetic background modulates behavioral impairments in R6/2 mice and suggests a role for dominant genetic modifiers in Huntington’s disease pathogenesis. Mamm Genome (2012) 0.77
Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes. Bioorg Med Chem Lett (2011) 0.76
Cerebellar soluble mutant ataxin-3 level decreases during disease progression in Spinocerebellar Ataxia Type 3 mice. PLoS One (2013) 0.75
Characterisation of human DP IV produced by a Pichia pastoris expression system. Adv Exp Med Biol (2003) 0.75
Acylated hydroxamates as selective and highly potent inhibitors of dipeptidyl peptidase I. Adv Exp Med Biol (2003) 0.75
Immuno-based detection assays to quantify distinct mutant huntingtin conformations in biological samples. Methods Mol Biol (2013) 0.75